68 related articles for article (PubMed ID: 22511276)
1. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
Kim MM; Dawood S; Allen P; Sahin AA; Woodward WA; Smith BD; Strom EA; Hunt KK; Meric-Bernstam F; Gonzalez-Angulo AM; Buchholz TA
Cancer; 2012 Oct; 118(20):4936-43. PubMed ID: 22511276
[TBL] [Abstract][Full Text] [Related]
2. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
Zhou Q; Yin W; Du Y; Lu J
PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
[TBL] [Abstract][Full Text] [Related]
3. Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study.
Lammers SWM; Meegdes M; Vriens IJH; Voogd AC; de Munck L; van Nijnatten TJA; Keymeulen KBMI; Tjan-Heijnen VCG; Geurts SME
ESMO Open; 2024 May; 9(5):103008. PubMed ID: 38677006
[TBL] [Abstract][Full Text] [Related]
4. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Esserman LJ; Berry DA; DeMichele A; Carey L; Davis SE; Buxton M; Hudis C; Gray JW; Perou C; Yau C; Livasy C; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; van 't Veer L; Hylton N
J Clin Oncol; 2012 Sep; 30(26):3242-9. PubMed ID: 22649152
[TBL] [Abstract][Full Text] [Related]
5. The 21-gene recurrence score and locoregional recurrence in breast cancer patients.
Jegadeesh NK; Kim S; Prabhu RS; Oprea GM; Yu DS; Godette KG; Zelnak AB; Mister D; Switchenko JM; Torres MA
Ann Surg Oncol; 2015 Apr; 22(4):1088-94. PubMed ID: 25472643
[TBL] [Abstract][Full Text] [Related]
6. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.
Freedman RA; Hughes ME; Ottesen RA; Weeks JC; He Y; Wong YN; Theriault R; Keating NL
Cancer; 2013 Feb; 119(4):839-46. PubMed ID: 23011924
[TBL] [Abstract][Full Text] [Related]
7. An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer.
Hui T; Li S; Wang H; Ma X; Du F; Gao W; Yang S; Sang M; Li Z; Ding R; Liu Y; Geng C
Oncologist; 2023 Dec; 28(12):e1160-e1169. PubMed ID: 37279952
[TBL] [Abstract][Full Text] [Related]
8. How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?
Norton N; Perez EA
Breast Cancer Res; 2013 Jan; 15(1):101. PubMed ID: 23316883
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Vaz-Luis I; Winer EP; Lin NU
Ann Oncol; 2013 Feb; 24(2):283-291. PubMed ID: 23022997
[TBL] [Abstract][Full Text] [Related]
10. Management of hormone receptor-positive, HER2-negative early breast cancer.
Walsh EM; Smith KL; Stearns V
Semin Oncol; 2020 Aug; 47(4):187-200. PubMed ID: 32546323
[TBL] [Abstract][Full Text] [Related]
11. Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial.
Glass CC; Pride RM; Freedman RA; Mayer EL; Ogayo ER; Chavez-MacGregor M; King TA; Mittendorf EA; Kantor O
Ann Surg Oncol; 2023 Dec; 30(13):8320-8326. PubMed ID: 37670122
[TBL] [Abstract][Full Text] [Related]
12. Using clinical trial data to tailor adjuvant treatments for individual patients.
Regan MM; Gelber RD;
Breast; 2007 Dec; 16 Suppl 2(Suppl 2):S98-104. PubMed ID: 17719227
[TBL] [Abstract][Full Text] [Related]
13. Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative HER2 normal metastatic breast cancer.
Altundag K
Med Oncol; 2024 May; 41(6):146. PubMed ID: 38727767
[No Abstract] [Full Text] [Related]
14. Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma.
Birts CN; Savva C; Laversin SA; Lefas A; Krishnan J; Schapira A; Ashton-Key M; Crispin M; Johnson PWM; Blaydes JP; Copson E; Cutress RI; Beers SA
Sci Rep; 2022 May; 12(1):7802. PubMed ID: 35610242
[TBL] [Abstract][Full Text] [Related]
15. Incidence of and Influencing Factors for Arm Lymphedema After Salvage Treatment for an Isolated Locoregional Recurrence of Breast Cancer.
Kim N; Kim H; Hwang JH; Lee JE; Park W; Cho WK; Nam SJ; Kim SW; Yu J; Chae BJ; Lee SK; Ryu JM; Im YH; Ahn JS; Park YH; Kim JY; Kim TG
J Breast Cancer; 2023 Dec; 26(6):544-557. PubMed ID: 37985381
[TBL] [Abstract][Full Text] [Related]
16. Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.
Fasching PA; Kreipe H; Del Mastro L; Ciruelos E; Freyer G; Korfel A; Chouaki N; Stoffregen C; Sapunar F; Cameron D
Geburtshilfe Frauenheilkd; 2024 Feb; 84(2):164-184. PubMed ID: 38344042
[TBL] [Abstract][Full Text] [Related]
17. Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
Williamson M; Press DJ; Hansen SA; Tomar A; Jhuti GS; Revil C; Gururaj K
Breast Cancer; 2024 Jan; 31(1):84-95. PubMed ID: 37907759
[TBL] [Abstract][Full Text] [Related]
18. Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery.
Cheun JH; Won J; Jung JG; Kim HK; Han W; Lee HB
J Breast Cancer; 2021 Jun; 24(3):301-314. PubMed ID: 34190441
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer:
Sun GY; Jing H; Wang SL; Song YW; Jin J; Fang H; Liu YP; Ren H; Tang Y; Zhao XR; Song YC; Chen SY; Yang ZB; Chen B; Tang Y; Li N; Lu NN; Qi SN; Yang Y; Li YX
Front Oncol; 2020; 10():605750. PubMed ID: 33575216
[TBL] [Abstract][Full Text] [Related]
20. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
